(ξ-4-methyl-cyclohexyl)-acetonitrile | 197091-12-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (ξ-4-methyl-cyclohexyl)-acetonitrile
• 英文别名: (ξ-4-Methyl-cyclohexyl)-acetonitril；2-(4-Methylcyclohexyl)acetonitrile
• CAS: 197091-12-6
• 化学式: C₉H₁₅N
• 分子量: 137.225
• InChiKey: CJERZJOXVLRLIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-甲基环己烷甲酸 在 lithium aluminium tetrahydride 、 溴 、 三苯基膦 作用下， 以 二甲基亚砜 为溶剂， 生成 (ξ-4-methyl-cyclohexyl)-acetonitrile
  参考文献：
  名称：

  Conformational preferences of some substituted methyl groups in cyclohexanes as studied by carbon-13 nuclear magnetic resonance

  摘要：

  AbstractLow temperature 13C NMR spectra of 80:20 mixtures of cis and trans‐4CH3CH3C6H10CH2X, where C6H10‐is 1, 4‐disubtituted cyclohexyl and X=Br, CN, OH, OCH3, Si(CH3)3, Sn(CH3)3, Pb(CH3)3 and HgOCOCH3 have been recorded. The signals of the trans (e, e) components were assigned from the ambient temperature spectra of C6H11CH2X and the established substituent effects of an equatorial methyl group in cyclohexane. Conformational equilibria of the cis (e, a⇄a, e) components were then computed from the intensities of the (remaining) signals (∼180 K) of the two conformational isomers. From these equilibria A values of CH2X were calculated, assuming additivity of conformational energies of CH3 and CH2X (the counter‐poise approach). In general, these values are very similar to the value of the CH3, although some trends do emerge. This study provides α, β, γ, and δ effects for a wide range of axial and equatorial CH2X groups.

  DOI：

  10.1002/mrc.1270150304

文献信息

• [EN] TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES TRICYCLIQUES, COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CES COMPOSÉS COMME INHIBITEURS DES JAK
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013007768A1

  公开（公告）日：2013-01-17

  The invention provides novel compounds of formula I having the general formula:(I) wherein Rl s R2, R3, X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.

  这项发明提供了具有一般公式(I)的新化合物，其具有以下通式：其中R1、R2、R3、X和Y如本文所述。因此，这些化合物可以以药学上可接受的组合物形式提供，并用于治疗免疫性或过度增殖性疾病。
• Spatial distribution of spin-labeled trichogin GA IV in the gram-positive bacterial cell membrane determined from PELDOR data
  作者：A. D. Milov、R. I. Samoilova、Yu. D. Tsvetkov、V. A. Gusev、F. Formaggio、M. Crisma、C. Toniolo、J. Raap

  DOI：10.1007/bf03166186

  日期：2002.10

  echo is used to study the spatial distribution of spin-labeled [TOAC-4]-trichogin GA IV analog bound to the cell membrane of the Gram-positive bacteriumMicrococcus luteus. The intermolecular dipole-dipole spin-spin interaction of TOAC spin labels has been experimentally studied at 77 K in glassy dispersions of the spherical cell particles. It is shown that the nonaggregated peptide molecules are distributed

  Trichogin GA IV 是一种最短的真菌来源的无环线性多肽抗生素，其特征是在 C 端存在三个 α-氨基异丁酸残基、一个 N-辛酰基和一个氨基醇。它的抗生素活性通常被认为是基于其自组装和膜修饰特性。电子自旋回波中的双电子-电子共振技术用于研究与革兰氏阳性菌藤黄微球菌的细胞膜结合的自旋标记的 [TOAC-4]-trichogin GA IV 类似物的空间分布。TOAC 自旋标记的分子间偶极-偶极自旋-自旋相互作用已在 77 K 下在球形细胞颗粒的玻璃状分散体中进行了实验研究。结果表明，未聚集的肽分子分布在细胞质膜上。
• Conjugate Addition Reactions Mediated by Samarium(II) Iodide
  作者：Gary A. Molander、Christina R. Harris

  DOI：10.1021/jo971047e

  日期：1997.10.1

  Samarium(II) iodide in conjunction with a catalytic low-valent transition metal species has been employed to promote the conjugate addition reaction of primary and secondary alkyl halides onto alpha,beta-unsaturated esters and amides. The method has been determined to be quite general and hence has been extended to the cyclization reactions of alkyl halides onto alpha,beta-unsaturated lactones, lactams

  碘化mar（II）与催化的低价过渡金属物质已被用于促进伯烷基卤和仲烷基卤化物在α，β-不饱和酯和酰胺上的共轭加成反应。已经确定该方法是非常通用的，因此已经扩展到烷基卤化物到α，β-不饱和内酯，内酰胺和腈上的环化反应。本文所述的环化反应提供了一种非常简单的方法，可以由简单的非环状前体以极好的非对映选择性并在非常温和的反应条件下合成官能化的碳环。
• Azepine inhibitors of Janus kinases
  申请人：Arvanitis G. Argyrios

  公开号：US20070149506A1

  公开（公告）日：2007-06-28

  The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了可调节Janus激酶活性并且在治疗与Janus激酶活性相关的疾病方面有用的化合物，包括但不限于免疫相关疾病、皮肤疾病、髓细胞增生性疾病、癌症和其他疾病。
• TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Babu Srinivasan

  公开号：US20110201593A1

  公开（公告）日：2011-08-18

  The invention provides novel compounds of formula I having the general formula: wherein R 1 , R 2 , R 3 , X and Y are as described herein. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment of immunological or hyperproliferative disorders.

  本发明提供了具有以下一般式的新化合物I： 其中R1、R2、R3、X和Y如本文所述。因此，这些化合物可以在药学上可接受的组合物中提供，并用于治疗免疫或过度增生性疾病。